On November 24, 2025, Dayra Therapeutics, a start-up focused on developing oral macrocyclic peptide therapeutics to treat a range of human diseases, announced a research collaboration with Biogen Inc.

Founded in 2024 by Versant Ventures through the firm’s Frontier Discovery Engine, Dayra combines its macrocycle discovery platform with computational design and modeling to advance novel macrocyclic peptides that selectively target disease-relevant proteins. Dayra has secured more than $70 million in committed funding, including $50 million of upfront capital from the Biogen collaboration, as well as an equity commitment from Versant.

The Wilson Sonsini team that advised Dayra Therapeutics on the transaction includes:

Technology Transactions
Farah Gerdes
Jordin Wilcher

Corporate
Phillip McGill
Karen Deschaine

Mergers & Acquisitions
Jason Breen

For more information, please see Dayra Therapeutics’ news release.